Andrés Barba

Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy

Alessio Cortellini, Biagio Ricciuti, Francesco Facchinetti et al. · Annals of Oncology · 2021 · 62 citations · Full text

Antibiotics, Medicine, Antibiotic Adjuvant +10

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Mariona Riudavets, Joaquín Mosquera, Rosario García‐Campelo et al. · Frontiers in Oncology · 2020 · 53 citations · Full text

Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients

Ivana Sullivan, Pau Riera, Marta Andrés et al. · Angiogenesis · 2019 · 47 citations

Vegf Gene Variants, Medicine, Pathology +9

Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).

Mariona Riudavets, Andrés Barba, Pablo Maroto et al. · Journal of Clinical Oncology · 2018 · 32 citations

Solid Tumors, Cancer Management, Immunology +19

Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

Carlos Zamora, Mariona Riudavets, Geòrgia Anguera et al. · Cancer Immunology Immunotherapy · 2021 · 14 citations · Full text

Cancer Immunosurveillance, Blood Platelet, Medicine +13